| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:Mito-apocynin (C11)
CAS:1254044-38-6
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:Mito-apocynin (C11)
CAS:1254044-38-6
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:(11-((4-Hydroxy-3-methoxybenzoyl)oxy)undecyl)triphenylphosphonium bromide
CAS:1254044-38-6
Purity:98+% Package:1g Remarks:NULL
|
| Company Name: |
Beijing Jin Ming Biotechnology Co., Ltd.
|
| Tel: |
010-60605840 |
| Email: |
psaitong@jm-bio.com |
| Products Intro: |
Product Name:Mito-apocynin (C11)
CAS:1254044-38-6
Purity:>=98% Package:25mg;100mg;5mg;50mg;10mg;1mL
|
|
| | Mito-apocynin (C11) Basic information |
| Product Name: | Mito-apocynin (C11) | | Synonyms: | Mito-apocynin (C11);(11-((4-Hydroxy-3-methoxybenzoyl)oxy)undecyl)triphenylphosphonium bromide;Mito apocynin (C11),Mitoapocynin (C11),Mito-apocynin (C-11) | | CAS: | 1254044-38-6 | | MF: | C37H44BrO4P | | MW: | 663.63 | | EINECS: | | | Product Categories: | | | Mol File: | 1254044-38-6.mol |  |
| | Mito-apocynin (C11) Chemical Properties |
| storage temp. | Inert atmosphere,Room Temperature | | form | Solid | | color | White to off-white |
| | Mito-apocynin (C11) Usage And Synthesis |
| Uses | Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function[1]. | | in vivo | Mito-apocynin-C11 (3 mg/kg; oral gavage; 3x/wk from 3 months of age until 15 months) markedly improves the coordinated motor function and olfactory function in LRRK2R1441G mice[1]. | Animal Model: | LRRK2R1441G mice[1] | | Dosage: | 3 mg/kg | | Administration: | Oral gavage; 3x/wk from 3 months of age until 15 months | | Result: | Markedly improved the coordinated motor function and olfactory function.
|
| | References | [1] Dranka BP, et al. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci Lett. 2014 Nov 7;583:159-64. DOI:10.1016/j.neulet.2014.09.042 |
| | Mito-apocynin (C11) Preparation Products And Raw materials |
|